ArticleJournal of nephrology2022
Nephrotoxic medications and associated acute kidney injury in hospitalized neonates.
Article in Journal of nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Incidence and risk factors of drug-induced kidney injury in children: a systematic review and meta-analysis.European journal of clinical pharmacology · 2023Pooled it
- Megalin (LRP2), prenatal betamethasone, and injury susceptibility in the developing kidney.bioRxiv : the preprint server for biology · 2026Article
- Low nephron number and high salt diet: the role of the "second hit" in chronic kidney disease development.Pediatric research · 2025Article
- Windows of susceptibility to neonatal acute kidney injury and nephron loss in a rabbit model.Scientific reports · 2025Article
- Pediatric Chronic Kidney Disease: Mind the Gap Between Reality and Expectations.Children (Basel, Switzerland) · 2025Review
- ADVANCE: a biomedical informatics approach to investigate acute kidney injury in infants.Pediatric research · 2025Article
- Preterm Birth and Kidney Health: From the Womb to the Rest of Life.Children (Basel, Switzerland) · 2024Review
- Artificial intelligence in early detection and prediction of pediatric/neonatal acute kidney injury: current status and future directions.Pediatric nephrology (Berlin, Germany) · 2024Review
- Pharmacovigilance of nephrotoxic drugs in neonates: the Pottel method for acute kidney injury detection in ELBW neonates.Pediatric nephrology (Berlin, Germany) · 2024Article
- Acute Kidney Injury in Neonatal Intensive Care Unit: Epidemiology, Diagnosis and Risk Factors.Journal of clinical medicine · 2024Review
- Human Nephrogenesis can Persist Beyond 40 Postnatal Days in Preterm Infants.Kidney international reports · 2024Article
- Risk of chronic kidney disease in children who developed acute kidney injury secondary to nephrotoxic medication exposure in infancy.Renal failure · 2023Article
- Sex differences in long-term kidney fibrosis following neonatal nephron loss during ongoing nephrogenesis.Molecular and cellular pediatrics · 2023Article
- Neonatal nephrotoxic medication exposure and early acute kidney injury: results from the AWAKEN study.Journal of perinatology : official journal of the California Perinatal Association · 2023Article
- Short-course empiric antibiotic therapy for possible early-onset sepsis in the NICU.Journal of perinatology : official journal of the California Perinatal Association · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesHospitalized neonates are often treated with nephrotoxic medications, a known risk factor for acute kidney injury (AKI). Nephrotoxic medications and AKI, especially in periviable neonates, could be detrimental to nephrogenesis. Our objectives were to evaluate the prevalence of neonatal treatment with nephrotoxic medications and its relationship with AKI in in the first 28 days of life, and to delineate the associated demographics and diagnoses. STUDY
designMulticenter retrospective analysis using the national Pediatric Hospital Information System database, including 49 pediatric hospitals. Neonates admitted within the first two postnatal days were included. Treatment with 37 nephrotoxic medications across demographics and clinical variables, and relationship with AKI were evaluated. AKI was determined by using the International Classification of Diseases codes.
resultsOf 192,229 neonates, 74% were treated with at least one nephrotoxic medication. Incidence of AKI was significantly higher in the treated group (aRR 3.68 [95% CI: 2.85, 4.75]). The aRRs of treatment were increased in infants born < 32-week, and < 2000 g. Nephrotoxic medications were prescribed to 90-95% of neonates born ≤ 28-week gestational age. Most treatments (95-98%) occurred in the first 3 days. Intravascular aminoglycosides were the most frequent type; 28% of neonates were treated for ≥ 4 calendar days. Most common diagnoses were infections (25%) and patent ductus arteriosus (20%).
conclusionsNeonatal treatment with nephrotoxic medications is common, especially among the smallest, most immature preterm neonates and demonstrates a need for initiatives to reduce neonatal exposure to these agents, when feasible. Across all gestational age categories, the prevalence of AKI is higher in the neonates treated with nephrotoxic drugs. The long-term effects of treatment with nephrotoxic medications and subsequent AKI on nephrogenesis and nephron endowment will need to be evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.